By Allison Grande (August 9, 2010, 5:27 PM EDT) -- The U.S. Food and Drug Administration has advised health care professionals to be vigilant of the risks associated with the long-term use of inferior vena cava filters, after receiving more than 900 adverse event reports involving the device since 2005.
The agency released an initial communication Monday, recommending that implanting physicians and clinicians responsible for the ongoing care of patients with retrievable IVC filters consider removing the filter as soon as protection from pulmonary embolism is no longer needed.
Since 2005, there have been 921 device adverse event reports related to IVC filters, of which 328 involved device migration, 146 involved...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!